^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit

Type:
CE Marked
Related tests:
Evidence

News

over1year
HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer (ESMO 2023)
Accuracy of BRCA1/2 SNV/InDel was further verified with 100% concordance with BRCA1/2 kit. Conclusions With high sensitivity and specificity, short TAT and high success rate, the CE marked (CE-IVD) HRD Complete assay provides a robust and reliable test approach to PC patients that may guide them for a better treatment option.
PARP Biomarker • BRCA Biomarker • Next-generation sequencing
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
|
AmoyDx® HRD Focus Panel • AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit